|
Quotes & Info
|
| GTXI > SEC Filings for GTXI > Form 8-K on 14-Feb-2013 | All Recent SEC Filings |
14-Feb-2013
Other Events, Financial Statements and Exhibits
On February 14, 2013, GTx, Inc. issued a press release announcing that new preclinical data will be presented on AKR1C3, as an androgen receptor-selective coactivator and promoter of growth in prostate cancer cells and castration resistant prostate cancer. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
(d) Exhibits
Exhibit Number Description 99.1 Press Release issued by GTx, Inc. dated February 14, 2013 |
|
|